1-4 of 4
Sergey Voloshin, MD
Close
Sort by
Journal Articles

Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs

Andreas Hochhaus, MD, Carla Boquimpani, MD, Delphine Rea, MDPhD, Yosuke Minami, MDPhD, Elza Lomaia, MD PhD, Sergey Voloshin, MD PhD, Anna G. Turkina, Prof., MD, Dong-Wook Kim, MD, Jane Apperley, FRCP, FRCPath, MB, Jorge E. Cortes, MD, Andre Abdo, MD, Laura Maria Fogliatto, MD PhD, Dennis Dong Hwan Kim, MD PhD, Philipp D le Coutre, MD, Susanne Saussele, MD, Mario Annunziata, MD, Timothy P. Hughes, MDMBBS,FRACP,FRCPA, Naeem A. Chaudhri, MD, Lynette C.Y. Chee, MBBS,PhDFRACP,FRCPA, Valentín García Gutiérrez, MD PhD, Koji Sasaki, MD, Paola Aimone, MD, Alex Allepuz, MD MPH, Sarah Quenet, Véronique Bédoucha, Michael J. Mauro, MD
Journal: Blood
Blood (2020) 136 (Supplement_2): LBA-4.
https://doi.org/10.1182/blood-2020-143816
Published: 2020
Journal Articles

Next-Generation Sequencing in Non- BCR-ABL Mechanisms Resistance in Patients with Chronic Myeloid Leukemia: Results of a Pilot Study

Ilya Buldakov, Sergey Voloshin, MD PhD, Mikhail Fominykh, MD, Vasily Shuvaev, MD, Sergey Petrov, Alexander Chechetkin, MD PhD, Irina Martynkevich, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 38–39.
https://doi.org/10.1182/blood-2020-142391
Published: 2020
Journal Articles

Next-Generation Sequencing Targeted Chronic Lymphocytic Leukemia Panel: A Pilot Study

Mariia Mikhaleva, MD, Irina Martynkevich, MD PhD, Sergey Petrov, Ilya Buldakov, Alexey Kuvshinov, MD, Vasily Shuvaev, MD, Alexander Chechetkin, MD PhD, Sergey Voloshin, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 19.
https://doi.org/10.1182/blood-2020-139418
Published: 2020
Journal Articles

Outcomes Following Lenalidomide for Relapsed/Refractory Mantle Cell Lymphoma Patients at Risk of Bleeding Events Because of Multiple Comorbidities or Treatment: A Post-Hoc Subgroup Analysis of the SPRINT (MCL-002) Trial

Marek Trneny, Thierry Lamy, MDPhD, Jan Walewski, MD PhD, David Belada, MD PhD, Jiri Mayer, John A Radford, MB ChB, MRCP, MD FRCP, Wojciech Jurczak, MD PhD, Franck Morschhauser, Julia Alexeeva, MD, Simon A. Rule, MD, Boris V Afanasyev, Professor, Kamil Kaplanov, Antoine Thyss, MD, Alexej Kuzmin, MD, Sergey Voloshin, MD, Kazimierz Kuliczkowski, prof., Agnieszka Giza, MD, Noel Milpied, MD PhD, Caterina Stelitano, MD, Reinhard Marks, MD, Lorenz Trümper, MD, Tsvetan Biyukov, MD, Evelyn Barnett, Marie-Laure Casadebaig Bravo, MSc, Luca Arcaini, MD
Journal: Blood
Blood (2016) 128 (22): 2978.
https://doi.org/10.1182/blood.V128.22.2978.2978
Published: 2016